Intraerythrocytic development of the human malaria parasite Plasmodium falciparum appears as a continuous flow through growth and proliferation. To develop a greater understanding of the critical regulatory events, we utilized piggyBac insertional mutagenesis to randomly disrupt genes. Screening a collection of piggyBac mutants for slow growth, we isolated the attenuated parasite C9, which carried a single insertion disrupting the open reading frame (ORF) of PF3D7_1305500. This gene encodes a protein structurally similar to a mitogen-activated protein kinase (MAPK) phosphatase, except for two notable characteristics that alter the signature motif of the dual-specificity phosphatase domain, suggesting that it may be a low-activity phosphatase or pseudophosphatase. C9 parasites demonstrated a significantly lower growth rate with delayed entry into the S/M phase of the cell cycle, which follows the stage of maximum PF3D7_1305500 expression in intact parasites. Genetic complementation with the full-length PF3D7_1305500 rescued the wild-type phenotype of C9, validating the importance of the putative protein phosphatase PF3D7_1305500 as a regulator of pre-S-phase cell cycle progression in P. falciparum.

Malara caused by Plasmodium falciparum infection is the major type of severe malaria and results in hundreds of thousands of deaths each year and hundreds of millions of clinical illnesses (1, 2). Within the infected individuals, asexual forms of the intraerythrocytic parasite grow rapidly through successive cycles of growth and proliferation. In each asexual generation, active entry into erythrocytes is followed by a growth phase culminating in dynamic release of erythrocyte-invading merozoites. The Plasmodium mitotic cycle is not fully understood and differs from the well-defined models established in yeast and mammalian cells (3). Observing the exact mitotic transitions during the cycle has been difficult due to variations in processes such as chromatid segregation, nuclear division, and spindle formation (4). However, this pattern of development has been observed in other members of the Apicomplexa, such as Toxoplasma gondii and Eimeria tenella, demonstrating the importance and conservation of this process across the phylum (5, 6).

In eukaryotic systems, phosphorylation cascades are critical to cellular development and depend on the coordinated activity of kinases, which are in turn modulated by the activity of phosphatases. There is growing evidence that kinases are critical regulators of cell growth and development in Plasmodium species (7–9). Plasmodium kinases, for example, have been found to be involved with the initial invasion of host cells in addition to egress and differentiation (6, 10). Additional studies have identified kinases in phosphorylation cascades of the gametocyte-ookinete-oocyst transition in the mosquito midgut (11–17). In contrast, few studies have described the phosphatases involved in these processes, which would understandably function with kinases to coregulate cell cycle progression at key checkpoints (18–22). This dearth of information about phosphatases may be due to a smaller relative number of identifiable phosphatases than of kinases in the Plasmodium genome (20, 23). However, it is not uncommon for phosphatases to be fewer due to their nonspecific mechanism of targeting phosphorylated substrates (24).

The protein tyrosine phosphatase (PTP) superfamily is defined by a conserved CX(R) motif located in a phosphate-binding pocket. Dual-specificity phosphatases (DUSPs) are a subset of this superfamily that includes the mitogen-activated protein kinase (MAPK) phosphatases (MKPs). MKPs are frequently involved in regulation of cell cycle progression, growth, and proliferation (25). One class of MKP is characterized by the presence of a non-catalytic N-terminal rhodanese (RHD)-like domain utilized for substrate recognition upstream from a catalytic DUSP domain (26–28). In P. falciparum, the PF3D7_1305500 gene is the only one encoding a product with these characteristics (20). In this study, we hypothesize that PF3D7_1305500 is an atypical MAPK phosphatase of P. falciparum expressed during intraerythrocytic development.

MATERIALS AND METHODS

In vitro parasite culture conditions. P. falciparum NF54 and mutant C9 clones were cultured according to standard methods at 37°C (5% O₂ and 5% CO₂, nitrogen balanced) in 5% hematocrit (O₂ blood) and RPMI 1640 medium with 0.5% Albumax II, 0.25% sodium bicarbonate, and...
0.01 mg/ml gentamicin (29). The C9 mutant parasite line was created by random insertional mutagenesis using the piggyBac transposon pXL-
BACII-HGDH. The location of the insertion in the PF3D7_1305500 open reading frame (ORF) was confirmed by thermal asymmetric interlaced (TAIL) sequence analysis.

**Determination of merozoite number per schizont.** Parasite cultures were double synchronized by standard methods using 5% sorbitol (29). Merozoites were counted in 300 singly infected segmented schizonts in Giemsa-stained thin smears from NF54 and C9 cultured parasites 40 h post-synchronization to determine the average number of merozoites produced per schizont.

**RNA extraction and analysis by qRT-PCR and RT-PCR.** NF54 RNA was collected from 6 intraerythrocytic developmental stages (early rings, late rings, early trophozoites, late trophozoites, early schizonts, and late schizonts [ER, LR, ET, LT, ES, and LS, respectively]) followed by saponin lysis, suspended in TRIzol reagent (Life Technologies), RNA purified, and treated with DNase I. Purity was confirmed by PCR carried out without the addition of reverse transcriptase (RT). PF3D7_1305500 was amplified using primers 5′-TCGATTTTGAGGAGCTGAA-3′ and 5′-GGTAAAATCATCCCTTTGTGT-3′ with the SuperScript III Platinum SYBR Green One-Step quantitative RT (qRT)-PCR kit (Life Technologies) following the manufacturer’s protocol. The relative expression of PF3D7_1305500 was then normalized against actin (PFL2215w). For RT-PCR analysis, 100 ng DNAse I-treated total RNA was amplified using primers 5′-CACCCTACCCCTGTA-3′ and 5′-GTATGATATTTATTATTATTATTATTTCGATTACCC-3′ along with a C-terminal hemagglutinin (HA) tag and a 3′UTR calmodulin (CAM) termination sequence. The transfection plasmid carried a blastocidin S deaminase (BSD) drug selection cassette under the control of the 3′UTR of the gene encoding histidine-rich protein (HRP3), and the 3′ UTR of the gene encoding histidine-rich protein-2 (HRP2) was used for drug selection. The vector included two inverted terminal repeat regions (ITR1 and ITR2), a feature included to promote the integration of a stable ORF as done in previous transgenic expression systems (30). Schizonts were isolated from a 20-ml culture with 3 to 5% parasitemia using a VarioMACS Separator (Miltenyi Biotec) and counted for each sample, and the data were analyzed using CFlow Plus software (BD Accuri). The cell cycle was determined by comparing the relative abundance of each developmental stage at each time point according to methods developed previously (33). The relative fold change was determined by calculating the fold increase in parasitemia between time zero and the endpoint. Each sample was then plotted as a percentage relative to NF54.

**Whole-genome sequencing.** To create a reference genome for the parental line, NF54 genomic DNA (gDNA) was converted into Illumina sequencing libraries using both PCR-free (34) and Kappa HiFi methods (35) in order to minimize the bias against AT-rich DNA that is introduced by PCR enzymes in standard Illumina sequencing methodologies. NF54 libraries were sequenced with 76-bp and 250-bp paired end reads on an Illumina HiSeq and MiSeq (ENA accession numbers ERS038926 and ERS184445, respectively). The sequence data were assembled into an NF54 reference genome using icorn (36), which iteratively mapped, compared, and corrected the reads against the P. falciparum 3D7 reference genome from GeneDB (37). Icorn ran 7 iterations and corrected 526 1-bp substitutions and >600 small insertion and deletions. Annotation was transferred onto this NF54 genome from the 3D7 reference using RATT (38).

An Illumina library was generated from PF3D7_1305500 mutant (C9) mutant strain gDNA using the Kappa HiFi amplification methodology and sequenced with 76-bp paired end reads on an Illumina HiSeq (ENA accession ERS038913). C9 and NF54 76 bp reads were mapped against the NF54 genome using SMART (http://www.sanger.ac.uk/resources/software/smart/; parameters: -r, 0; -i, 800; -y, 0,9; index was done with -k of 13 and -s of 3); 90.2% and 89.7% of reads mapped to the NF54 genome, with an average coverage of 54× and 57×, respectively, for the NF54 and C9 data. To identify locations where C9 differed from the parental NF54 genome, we merged the two BAM files using individual read group and run gatk (39) to realign the reads and call variants using the Plasmodium falciparum settings. Variations were called when the quality score was higher than 60 and when both samples had 10 or more reads mapping to the potential variant locus.

Illumina sequence data were also used to confirm the location of the piggyBac insertion site in the C9 genome. The sequence of the piggyBac transposon was added to the NF54 genome sequence, and then the C9 reads were mapped against this combined genome with SMART using the -x parameter, which maps each read pair independently. We then searched for mate pairs in which one read mapped to the piggyBac sequence and the other within the reference genome.

**Multiple alignments and phylogenetic analysis.** The sequence of PF3D7_1305500 and orthologous Plasmodium sequences were retrieved from PlasmoDB v9.2 (www.plasmodb.org). Outlier species were identified through BLAST searches with the DUSP domain using NCBI BLASTP. Sequences with the greatest homology to the PF3D7_1305500 settings. Variations were called when the phylogenetic tree created using the neighbor-joining method with 1,000 bootstrap replicates MEGA5 (42–44).

**RESULTS**

**Identification of an attenuated growth mutant in P. falciparum.** A collection of unique mutant clones was created from a laboratory line of P. falciparum NF54 using random insertional mutagenesis with a piggyBac transposon (31). The C9 parasite line carried one copy of a piggyBac transposon (pXL-BACII-HGDH) inserted at the TTTA A nucleotides 191 to 202 downstream of the start codon at the 5′ end of the single ORF of PF3D7_1305500 (Fig. 1A) (see the supplemental material). Intraerythrocytic growth for clone C9 was analyzed and determined to be severely attenuated with a net growth rate consistently ~50% of the NF54 parent (Fig. 1B). The growth-attenuating mutation in C9, though serious, is not fatal and allows the parasites to develop in a seemingly normal pattern in culture. During development, intraerythrocytic stages did not demonstrate any obvious differences in morphological characteristics (Fig. 2A), and the mean numbers of merozoites produced did not vary significantly from those of the NF54 parent (Fig. 2B). It was apparent that each cycle of the mutant parasite required a longer development time, but otherwise,
the organism appeared morphologically similar in Giemsa-stained thin blood smears. While the longer cell cycle length can account for some of the lower growth rate, the merozoites also appear to have a lower invasion rate.

**Defining characteristics of PF3D7_1305500 MKP.** The protein encoded by PF3D7_1305500 was determined to have two key structural features, an RHD domain followed by a DUSP-like domain. Bioinformatics analysis defined this tandem arrangement as characteristic of certain MKPs conserved within humans and other model organisms such as fruit fly and yeast (45–48). It is for this reason that we refer to the PF3D7_1305500 product as MKP1. The conserved signature motif of CX$_5$R, which aligns with isoleucine-398 (I398) in PF3D7_1305500. Duration of the catalytic triad aspartate-345 (D345) are conserved and amino acid residue cysteine-383 (C383) along with another residues of the catalytic triad aspartate-345 (D345) are conserved and align with conserved cysteine and aspartic acid of the other identified DUSPs. However, the third conserved catalytic residue, arginine, aligns with isoleucine-398 (I398) in PF3D7_1305500. During dephosphorylation, the conserved arginine is critical for dephosphorylation activity, since active DUSP domains often depend on arginine to maintain the transition state with the phosphorylated substrate (28). Absence of arginine is expected to drastically reduce the catalytic activity of the DUSP; therefore, this is an important departure from the consensus motif defined for catalytically active DUSP domain orthologs and would be expected to reduce phosphatase activity (28, 49).

Prior mutagenesis studies and analyses of catalytic domains in the DUSPs of model organisms suggest that unique characteristics, such as the ones identified in PF3D7_1305500, may be characteristic of a pseudophosphatase or a low-activity phosphatase (50–52). Additionally, there is an insertion of nine residues disrupting the spacing within the CX$_5$R signature motif. Though it cannot be determined if this insertion changes the three-dimensional structure within the putative binding pocket, this unique stretch of residues is conserved in each of the *Plasmodium* orthologs. Conservation of these unique characteristics in *Plasmodium* species supports the formation of an individual clade (Fig. 3B).

**PF3D7_1305500 regulates transition from pre-S phase to S/M phase.** In wild-type parasites, the highest relative abundance of PF3D7_1305500 transcripts is at the end of the pre-S developmental phase (i.e., late trophozoite) during intraerythrocytic development (33). This expression profile coincides with the stage when the C9 mutant cycle deviates from the wild-type cell cycle (Fig. 4). Utilizing the detailed time course experimental protocol developed previously (33), the timing for NF54 was determined to be 46 h compared to 52 h in the C9 MKP-null mutant. The difference resulted entirely from a prolonged pre-S trophozoite stage causing late entry into the S/M schizont phase. The duration of schizont development (S/M – C) was similar in C9 and NF54, making pre-S phase the only abnormal growth phase of the intraerythrocytic cycle (Fig. 5).

**Phenotype rescue of wild-type growth by genetic complementation.** Attenuated growth of the C9 MKP-null mutant remained stable over multiple subsequent generations, suggesting that survival was not due to phenotype reversion. This is consistent with general experience using the piggyBac system as it is now extensively used in a number of organisms, and the transposable elements remain integrated in the genome in the absence of transposase (31, 54–58). However, the extended maintenance of *P. falciparum* intraerythrocytic cultures required for transfection and the selection process in the experimental studies increases the possibility for secondary mutations to alter the cell cycle or cause growth attenuation. Therefore, to validate that the phenotype was due to disruption of PF3D7_1305500, we genetically complemented the C9 mutant with a full-length copy of PF3D7_1305500, including its putative promoter region (Fig. 6A). The 700-bp 5′ intergenic region between PF3D7_1305500 and the upstream gene MAL13P1.28 was added to the ORF to ensure that the native promoter was included. Using the BSD resistance marker on the

---

**FIG 1** The growth phenotype of the C9 mutant parasite is due to disruption of PF3D7_1305500. (A) Schematic of PF3D7_1305500 disrupted by a single insertion of the piggyBac transposon. Tandem RHD and DUSP domains are characteristic of MKPs. (B) Calculation of fold change reveals that the knockout of PF3D7_1305500 resulted in a reduced fold change of ~50% relative to NF54.

**FIG 2** Morphological analysis of the C9 mutant compared to NF54. (A) Comparison of Giemsa-stained thin blood smears of the wild-type parent NF54 and C9 did not reveal an obvious difference in major developmental stages. The hours postinvasion indicated in the micrographs are as follows: ER, 8 h; LR, 16 h; ET, 24 h; LT, 32 h; ES, 40 h; LS, 48 h. (B) Average merozoite counts in segmented schizonts of NF54 and C9 were not statistically different.
complement vector, we were able to select for two independent cloned lines, E3 and E8. RT-PCR analysis of both E3 and E8 revealed that the complemented parasite lines transcribed PF3D7_1305500, in contrast to what occurred with C9, which did not have detectable transcripts (Fig. 6B). By Southern blotting hybridization analysis, it was also determined that the complemented parasite lines maintained the full-length copy of PF3D7_1305500 as stable episomes (data not shown). This finding was also confirmed by whole-genome sequencing of the mutant and complemented parasite lines (Table 1). Forty-four positions met the criteria as potential differences between the C9 and parent strains, comprising 40 single-nucleotide polymorphisms (SNPs) and 4 indels. Of these potential variants, only 11 occurred within open reading frames. Closer examination of these 11 revealed that 9 fall into low-complexity regions, repetitive sequence and homopolymer tracts, and hence clear calling of variants is not possible. Only 2 SNPs were confirmed in coding sequences outside such low-complexity regions, one in PF3D7_0704000 and one in PF3D7_0730300. PF3D7_0704000 is a conserved protein of unknown function, and C9 contains a nonsynonymous mutation (D to Y) at position 4201 of the predicted protein sequence. PF3D7_0730300 is a member of the AP2 family of transcription factors that is known to play a role in liver stage parasite development, but with no known role in blood stage parasites. C9 contains a nonsynonymous mutation (G to E) at position 3047 of the predicted protein, which is near the C terminus of the protein and well outside the AP2 DNA binding domains. Using the Illumina sequence data to confirm the location of the piggyBac insertion site confirmed only a single piggyBac insertion site in the C9 genome, at position 271000 of chromosome 13. Complementation of the C9 mutant with the full-length copy of PF3D7_1305500 rescued the phenotype of both E3 and E8 as

FIG 3 Multiple alignment and phylogenetic analysis of PF3D7_1305500. (A) Alignment of PF3D7_1305500 with its Plasmodium orthologs and outlier species showing the conservation of catalytic residues (boxes). Cysteine and aspartic acid align with all homologs. Isoleucine aligns with the position of the conserved arginine and is conserved in all species of Plasmodium. A string of residues (bracket) are inserted into the signature motif and are conserved among the Plasmodium orthologs. (B) Phylogenetic analysis using the neighbor-joining method with 1,000 bootstrap replicates shows grouping of the Plasmodium sequences independent of the other species, suggesting an early divergence in the evolutionary lineage.

FIG 4 Transcription profile of PF3D7_1305500. Analysis by qRT-PCR showed that expression of PF3D7_1305500 has its highest expression relative to actin during the late trophozoite stage 32 h postinvasion. This stage corresponds to late pre-S development, during which the cell cycle of null mutants deviates from the wild-type development pattern. The time points 8, 16, 24, 32, 40, and 48 h postinvasion correspond to ER, LR, ET, LT, ES, and LS, respectively.
DISCUSSION

Cell cycle progression in *P. falciparum* and completion of intraerythrocytic development is highly dependent on a precise pattern of metabolic events. Disruption of any of the numerous biochemical pathways and processes is anticipated to have detrimental effects on the efficiency of this process. In our study, we discovered that normal cell cycle development was delayed by disruption of PF3D7_1305500, indicating that this atypical phosphatase is a regulator of the *P. falciparum* cell cycle. The delayed transition from the pre-S trophozoite to the S/M schizont suggests this transition phase during the parasite’s intraerythrocytic growth is a cell cycle checkpoint. Rescuing the phenotype in the null mutant through genetic complementation validated the notion that the attenuated phenotype was due to disruption of PF3D7_1305500.

Considering the attenuated phenotype along with the homology found between PF3D7_1305500 and the other well-characterized MKPs, it can be suggested that this putative atypical phosphatase might fulfill a similar function regulating MAPK in *Plasmodium*. MKPs of similar structure are often involved in signaling pathways, which is a likely function of PF3D7_1305500 (20, 59). Investigations in yeast demonstrate that MKPs are critical components of various signal transduction pathways that regulate transcription and maturation, which can also have an influence on the cell cycle (45, 46). Disruption of such functions in *P. falciparum* could produce the phenotype observed in C9. This domain structure is not evident in any other gene in the *P. falciparum* genome, but single-copy orthologs are evident in all of the other *Plasmodium* species with completed genomes, suggesting that its function is conserved among all malaria parasites. The presence of
TABLE 1 Whole-genome sequencing data for NF54, C9, and the complemented parasite lines

| Clone | Chromosome | Position | Presence of piggyBac insertion | Gene          | Episomal complementation | No. of unique SNPs | SNP genes                      |
|-------|------------|----------|--------------------------------|---------------|--------------------------|-------------------|-------------------------------|
| NF54  | 13         | 271000   | No                             | None          | No                       | 0                 | PF3D7_0704000, PF3D7_0730300  |
| C9    | 13         | 271000   | Yes                            | PF3D7_1305500 | No                       | 2                 | PF3D7_0704000, PF3D7_0730300  |
| E3    | 13         | 271000   | Yes                            | PF3D7_1305500 | Yes                      | 2                 | PF3D7_0704000, PF3D7_0730300  |
| E8    | 13         | 271000   | Yes                            | PF3D7_1305500 | Yes                      | 2                 | PF3D7_0704000, PF3D7_0730300  |

A single SNP in the putative clathrin coat assembly protein AP180 was present in all samples. This experiment also validated that the complementation of C9 was episomal.

ACKNOWLEDGMENTS

We acknowledge the valuable contributions of support from Mandy Sanders and Matthew Berrian from the Wellcome Trust Sanger Institute for assistance in the whole-genome sequencing.

This study was supported by funds from the U.S. National Institutes of Health (R01AI036356 and R01AI094973 to J.H.A. and F31AI083053 to C.C.), European 7th framework EviMalaR (to T.D.O.), and The Wellcome Trust (to J.C.R.).

B.B., C.C., and J.H.A. designed the research. B.B., C.C., J.S., S.M., N.S., P.T., and A.P. performed the research. B.B., C.C., J.C.R., A.P., and J.H.A. analyzed the data; and B.B., C.C., and J.H.A. wrote the paper.

REFERENCES

1. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI. 2005. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434:214–217.

2. WHO. 2011. World Malaria Report 2011. World Health Organization, Geneva, Switzerland. http://www.who.int/malaria/world_malaria_report_2011/

3. Arnott DE, Gull K. 1998. The Plasmodium cell-cycle: facts and questions. Ann. Trop. Med. Parasitol. 92:361–365.

4. Arnott DE, Ronander E, Bengtsson DC. 2011. The progression of the intra-erythrocytic cell cycle of Plasmodium falciparum and the role of the centriolar plaques in asynchronous mitotic division during schizogony. Int. J. Parasitol. 41:71–80.

5. Ng ST, Sanusi Jangi M, Shirley WM, Tomley FM, Wan KL. 2002. Comparative EST analyses provide insights into gene expression in two asexual developmental stages of Eimeria tenella. Exp. Parasitol. 101:168–173.

6. Lim DC, Cooke BM, Doerig C, Saeij JP. 2012. Toxoplasma and Plasmodium protein kinases: roles in invasion and host cell remodelling. Int. J. Parasitol. 42:212–32.

7. Lucet IS, Tobin A, Drewry D, Wilks AF, Doerig C. 2012. Plasmodium kinases as targets for new-generation antimalarials. Future Med. Chem. 4:2295–2310.

8. Ma J, Rahlis S, Jortzik E, Schirmer RH, Przyborski JM, Becker K. 2012. Subcellular localization of adenylate kinases in Plasmodium falciparum. FEBS Lett. 586:3037–3043.

9. Rached FB, Ndjembo-Ezougu C, Chandran S, Talabani H, Yera H, Dandavate V, Bourdoncle P, Meissner M, Tatu U, Langsley G. 2012. Construction of a Plasmodium falciparum Rab-interactome identifies CK1 and PKA as Rab-effector kinases in malaria parasites. Biol. Cell 104:34–47.

10. Dvorin JD, Martyn DC, Patel SD, Grimley JS, Collins CR, Hopp CS, Bright AT, Westenberger S, Winzeler E, Blackman MJ, Baker DA, Wadland TJ, Duraisingh MT. 2010. A plant-like kinase in Plasmodium falciparum regulates parasite egress from erythrocytes. Science 328:910–912.
11. Dorin-Semblat D, Schmitt S, Semblat JP, Sicard A, Reineiger L, Goldring D, Patterson S, Quaschke N, Chakrabarti D, Meijer L, Doerig C. 2011. Plasmodium falciparum NIMA-related kinase Pfnek-1: sex specificity and assessment of essentiality for the erythrocytic asexual cycle. Microbiology 157:2785–2794.

12. Reineiger L, Garcia M, Tomlins A, Muller S, Doerig C. 2012. The Plasmodium falciparum, Nima-related kinase Pfnek-4: a marker for asexual parasites committed to sexual differentiation. Malaria J. 11:250. doi: 10.1186/1475-2875-11-250.

13. Sebastian S, Brochet M, Collins MO, Schwach F, Jones ML, Goulding M, Garcia M, Tomlins A, Muller S, Doerig C. 2012. The Plasmodium falciparum, Nima-related kinase Pfnek-4: a marker for asexual parasites committed to sexual differentiation. Malaria J. 11:250. doi: 10.1186/1475-2875-11-250.

14. Alano P. 2007. Plasmodium falciparum gametocytes: still many secrets of a hidden life. Mol. Microbiol. 66:291–302.

15. Tewari R, Deschamps S, Tewari R, Wenig E, Franke-Fayard B, Brinkmann V. 2004. Calcium and a calcium-dependent protein kinase regulate gamete formation and mosquito transmission in a malaria parasite. Cell 117:503–514.

16. Mamoun CB, Goldberg DE. 2001. Plasmodium protein phosphatase 2C dephosphorylates translation elongation factor Ibeta and inhibits its PKC-mediated nucleotide exchange activity in vitro. Mol. Microbiol. 39:973–981.

17. Yokoyama D, Saito-Ito A, Asao N, Tanabe K, Yamamoto M, Matsumura T. 1998. Modulation of the growth of Plasmodium falciparum in vitro by protein serine/threonine phosphatase inhibitors. Biochem. Biophys. Res. Commun. 247:18–23.

18. Wilkes JM, Doerig C. 2008. The protein-phosphatome of the human malaria parasite Plasmodium falciparum. BMC Genomics 9:412. doi: 10.1186/1471-2164-9-412.

19. Hills T, Srivastava A, Ayi K, Wernimont AK, Kain K, Waters AP, Hui Chung DW, Ponts N, Cervantes S, Le Roch KG. 2010. The systematic functional analysis of Plasmodium falciparum. BMC Genomics 11:89–97.

20. Alano P. 2007. Plasmodium falciparum gametocytes: still many secrets of a hidden life. Mol. Microbiol. 66:291–302.

21. Guttery DS, Poulin B, Ferguson DJ, Szoor B, Wickstead B, Carroll PL, Ramakrishnan C, Brady D, Patzwitz EM, Strachil S, Solyakov L, Green JL, Sinden RE, Tobin AB, Holder AA, Tewari R. 2012. A unique protein phosphatase with kelch-like domains (PPKL) in Plasmodium modulates ookinet differentiation, motility and invasion. PLoS Pathog. 8:e1002948. doi: 10.1371/journal.ppat.1002948.

22. Chung DW, Potts N, Cervantes S, Le Roch KG. 2009. Post-translational modifications in Plasmodium: more than you think? Mol. Biochem. Parasitol. 168:123–134.

23. Almo SC, Bonanno JB, Sauder JM, Emtage S, Dilorenzo TP, Malashkevich V, Wasserman SR, Swaminathan S, Eswaramoorthy S, Agarwal R, Kumanar D, Madegowda M, Raguman S, Patskovsky Y, Alvarado J, Ramagopal UA, Faber-Barata J, Chance MR, Sali A, Fiser A, Zhang ZY, Lawrence DS, Burley SK. 2007. Structural genomics of protein phosphatases. J. Struct. Funct. Genomics 8:121–140.

24. Kondoh K, Nishida E. 2007. Regulation of MAP kinases by MAP kinase phosphatases. Biochem. Biophys. Acta 1773:1227–1237.

25. Farooq A, Chaturvedi G, Mujtaba S, Plotnikova O, Zeng L, Dhulluin C, Ashton R, Zhou MM. 2001. Solution structure of ERK2 binding domain of MAPK phosphatase MAPK-3: structural insights into MAPK-3 activation by ERK2. Mol. Cell 7:387–399.

26. Farooq A, Zhou MM. 2004. Structure and regulation of MAPK phosphatases. Cell Signal. 16:769–779.

27. Theodosiou A, Ashworth A. 2002. MAP kinase phosphatases. Genome Biol. 3:REVIEWS3001.

28. Malaria Research and Reference Reagent Resource Center. 2008. Methods in malaria research, vol 5.2. Malaria Research and Reference Reagent Resource Center, Paris, France.

29. Balu B, Adams JH. 2006. Functional genomics of Plasmodium falciparum through transposon-mediated mutagenesis. Cell. Microbiol. 8:1529–1536.

30. Balu B, Shoue DA, Fraser MJ, Jr, Adams JH. 2005. High-efficiency transformation of Plasmodium falciparum by the lepidopteran transposable element piggyBac. Proc. Natl. Acad. Sci. U. S. A. 102:16391–16396.

31. Balu B, Singh N, Maher SP, Adams JH. 2010. A genetic screen for attenuated growth identifies genes crucial for intrarherocytic development of Plasmodium falciparum. PLoS One 5:e13282. doi:10.1371/journal.pone.0013282.

32. Russo I, Oksman A, Vaupel B, Goldberg DE. 2009. A calpain unique to alveolates is essential in Plasmodium falciparum and its knockdown reveals an involvement in pre-S-phase development. Proc. Natl. Acad. Sci. U. S. A. 106:1554–1559.

33. Kozarewa I, Ning Z, Quail MA, Sanders MJ, Berriman M, Turner DJ. 2009. Amplification-free Illumina sequencing-library preparation facilitates improved mapping and assembly of (G+C)-biased genomes. Nat. Methods 6:291–295.

34. Oyola SO, Otto TD, Gu Y, Maslen G, Manske M, Campbell, S, Turner DJ, Macinnis B, Kwiatkowski DP, Swerdlow HP, Quail MA. 2012. Optimizing Illumina next-generation sequencing library preparation for extremely AT-biased genomes. BMC Genomics 13:1. doi:10.1186/1471-2164-13-1.

35. Otto TD, Sanders M, Berriman M, Newbold C. 2010. Iterative Correction of Reference Nucleotides (iCORN) using second generation sequencing technology. Bioinformatics 26:1704–1707.

36. Logan-Klumper FJ, De Silva N, Boehme U, Rogers MB, Velarde G, McQuillan JA, Carver T, Aslett M, Olsen C, Subramanian S, Phan I, Farris C, Mitra S, Ramasamy G, Wang H, Tivey A, Jackson E, Brenchley J, Parkhill J, Holdon M, Harb OS, Bruhn B, Myler PL, Roos D, Carrington M, Smith DF, Hertz-Fowler C, Berriman M. 2012. GeneDB—an annotation database for pathogens. Nucleic Acids Res. 40:D98–D108.

37. Otto TD, Dillon GP, Degrave WS, Berriman M. 2011. RATT: Rapid Annotation Transfer Tool. Nucleic Acids Res. 39:e57. doi:10.1093/nar/gkt1268.

38. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Gammill J, Groth JR, Arino J. 2012. Novel protein phosphatases in yeast. Eur. J. Biochem. 240:26782–26785.

39. Tamura K, Dudley J, Nei M, Kumar S. 2007. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol. Biol. Evol. 24:1596–1599.

40. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. 2011. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol. Biol. Evol. 28:2713–2721.

41. Martin H, Flandez M, Nombela C, Molina M. 2005. Protein phosphatases in MAPK signalling: we keep learning from yeast. Mol. Microbiol. 58:6–16.

42. Kim Y, Gentry MS, Harris TE, Wiley SE, Lawrence JC, Jr, Dixon JE. 2007. A conserved phosphatase cascade that regulates nuclear membrane and cytokinesis. Mol. Biol. Cell. 18:16391–16396.

43. Gustin MC, Albertson J, Alexander M, Davenport K. 1998. MAP kinase pathways in the yeast Saccharomyces cerevisiae. Microbiol. Mol. Biol. Rev. 62:1264–1300.

44. Arino J. 2002. Novel protein phosphatases in yeast. Eur. J. Biochem. 269:1072–1077.

45. Denu JM, Dixon JE. 1998. Protein tyrosine phosphatases: mechanisms of catalysis and regulation. Curr. Opin. Chem. Biol. 2:633–641.

46. Wishart MJ, Denu JM, Williams JA, Dixon JE. 1995. A single mutation converts a novel phosphotyrosine binding domain into a dual-specificity phosphatase. J. Biol. Chem. 270:26782–26785.

47. Wishart MJ, Dixon JE. 1998. Gathering STYX: phosphatase-like form predicts functions for unique protein-interaction domains. Trends Biochem. Sci. 23:301–306.
52. Tonks NK. 2009. Pseudophosphatases: grab and hold on. Cell 139:464–465.
53. Otto TD, Wilinski D, Assefa S, Keane TM, Larry SR, Bohme U, Lemieux J, Barrell B, Pain A, Berriman M, Newbold C, Llinas M. 2010. New insights into the blood-stage transcriptome of Plasmodium falciparum using RNA-Seq. Mol. Microbiol. 76:12–24.
54. Fraser MJ, Ciszczon T, Elick T, Bauser C. 1996. Precise excision of TTAA-specific lepidopteran transposons piggyBac (IFP2) and tagalong (TFP3) from the baculovirus genome in cell lines from two species of Lepidoptera. Insect Mol. Biol. 5:141–151.
55. O’Brochta DA, Atkinson PW. 1996. Transposable elements and gene transformation in non-drosophilid insects. Insect Biochem. Mol. Biol. 26:739–753.
56. Morales ME, Mann VH, Kines KJ, Gobert GN, Fraser MJ, Jr, Kalinna BH, Correnti JM, Pearce EJ, Brindley PJ. 2007. piggyBac transposon mediated transgenesis of the human blood fluke, Schistosoma mansoni. FASEB J. 21:3479–3489.
57. Sethuraman N, Fraser MJ, Jr, Eggleston P, O’Brochta DA. 2007. Post-integration stability of piggyBac in Aedes aegypti. Insect Biochem. Mol. Biol. 37:941–951.
58. Fonager J, Franke-Fayard BM, Adams JH, Ramesar J, Klop O, Khan SM, Janse CJ, Waters AP. 2011. Development of the piggyBac transposable system for Plasmodium berghei and its application for random mutagenesis in malaria parasites. BMC Genomics 12:155. doi:10.1186/1471-2164-12-155.
59. Kozlov S, Waters NC, Chavchich M. 2010. Leveraging cell cycle analysis in anticancer drug discovery to identify novel plasmodial drug targets. Infect. Disord. Drug Targets 10:165–190.
60. Andreeva AV, Kutuzov MA. 2008. Protozoan protein tyrosine phosphatases. Int. J. Parasitol. 38:1279–1295.
61. Wishart MJ, Dixon JE. 2002. The archetype STYX/dead-phosphatase complexes with a spermatid mRNA-binding protein and is essential for normal sperm production. Proc. Natl. Acad. Sci. U. S. A. 99:2112–2117.
62. Hinton SD, Myers MP, Roggero VR, Allison LA, Tonks NK. 2010. The pseudophosphatase MK-STYX interacts with G3BP and decreases stress granule formation. Biochem. J. 427:349–357.
63. Cheng KC, Klancer R, Singson A, Seydoux G. 2009. Regulation of MK-2/DYRK by CDK-1 and the pseudophosphatases EGG-4 and EGG-5 during the oocyte-to-embryo transition. Cell 139:560–572.
64. Kutuzov MA, Andreeva AV. 2008. Protein Ser/Thr phosphatases of parasitic protozoa. Mol. Biochem. Parasitol. 161:81–90.
65. Hyde JE. 2005. Drug-resistant malaria. Trends Parasitol. 21:494–498.
66. Dondorp AM, Yeung S, White L, Nguon C, Day NP, Socheat D, von Seidlein L. 2010. Artemisinin resistance: current status and scenarios for containment. Nat. Rev. Microbiol. 8:272–280.
67. Ekland EH, Fidock DA. 2008. In vitro evaluations of antimalarial drugs and their relevance to clinical outcomes. Int. J. Parasitol. 38:743–747.
68. Gamo FJ, Sanz LM, Vidal J, de Cozar C, Alvarez E, Lavandera JL, Vanderwall DE, Green DV, Kumar V, Hasan S, Brown JR, Peishoff CE, Cardon LR, Garcia-Bustos JF. 2010. Thousands of chemical starting points for antimalarial lead identification. Nature 465:305–310.
69. Jensen K, Plichta D, Panagiotou G, Kouskoumvekaki I. 2012. Mapping the genome of Plasmodium falciparum on the drug-like chemical space reveals novel anti-malarial targets and potential drug leads. Mol. Biosyst. 8:1678–1685.
70. Stepniewska K, Ashley E, Lee SJ, Anstey N, Barnes KI, Binh TQ, D’Alessandro U, Day NP, de Vries PJ, Dorsey G, Guthmann JP, Mayxay M, Newton PN, Olliaro P, Osorio I, Price RN, Rowland M, Smithuis F, Taylor WR, Nosten F, White NJ. 2010. In vivo parasitological measures of artemisinin susceptibility. J. Infect. Dis. 201:570–579.